Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886862 | 0.92 | MAPK8 (0.40) | MAPTTP53MAPK8LMNAALDH1A1 | |
| SCHEMBL5886931 | 0.91 | MAPK8 (0.41) | MAPTMAPK8LMNAALDH1A1MAPK14 | |
| SCHEMBL5886854 | 0.91 | SMN1; SMN2 (0.43) | MAPTPOLBALDH1A1 | |
| SCHEMBL5886787 | 0.90 | RORC (0.41) | TP53MAPK8LMNAALDH1A1 | |
| SCHEMBL5887103 | 0.86 | MAPK14 (0.35) | MAPK8LMNAPOLBALDH1A1MAPK14 | |
| SCHEMBL5887323 | 0.86 | MAPK14 (0.40) | MAPK8PTGER1MAPK14 | |
| SCHEMBL5887357 | 0.83 | MAPK14 (0.47) | MAPTTP53MAPK8LMNARXFP1 | |
| SCHEMBL5887454 | 0.83 | PDE4B (0.38) | MAPTTP53MAPK8LMNAMAPK14 | |
| SCHEMBL5886768 | 0.83 | HPGD (0.47) | MAPTTP53LMNARXFP1POLB | |
| SCHEMBL5886789 | 0.82 | HPGD (0.47) | MAPTTP53MAPK8LMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAPT 1614/4885TP53 43/4885MAPK8 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.